Illumina Inc. (ILMN)

Business: Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

IPO Date: 28-Jul-2000

CEO & Director: Mr. Francis A. deSouza

CTO & Head of Research and Product Devel.: Dr. Alexander Aravanis M.D., Ph.D.

Listing: NASDAQ: ILMN

Country: United States

Headquarters: San Diego, CA

Website: https://www.illumina.com

Market cap: $35,154.27 Mln

Revenue (TTM): $4,656.00 Mln

Earnings (TTM): $700.00 Mln

Cash: $1,416.00 Mln

Total Debt: $2,615.00 Mln

Insider's Holding: 0.36%

Liquidity: Low

52 Week range: $173.45 - 526.00

Shares outstanding: 157,100,000

10 Years Aggregate:

• CFO: $7,437.60 Mln
• EBITDA: $8,855.55 Mln
• Net Profit: $5,526.21 Mln